Cours | Graphes | News | Analyses et conseils | Historiques | Vie du titre | Forum |
Répondre
|
Répondre
|
Répondre
|
Répondre
|
Répondre
|
Répondre
|
Répondre
|
Répondre
|
Message complété le 22/02/2014 17:16:19 par son auteur.
ps: peut être
Répondre
|
Répondre
|
Répondre
|
Répondre
|
Répondre
|
Message complété le 21/02/2014 17:15:54 par son auteur.
PHARM vient de recevoir une autorisation pour l'ISRAEL:
source: http://www.pharming.com/
Pharming’s Partner, MegaPharm, Receive Marketing Authorisation For Ruconest® In Israel And Full Reimbursement
Leiden, The Netherlands, 15 January 2014. Biotech company Pharming Group NV (“Pharming”) (NYSE Euronext: PHARM) today announced that its partner, MegaPharm Ltd (MegaPharm), a privately owned Israeli pharmaceutical company, has received marketing approval for RUCONEST® (recombinant human C1 inhibitor) in Israel. The indication as approved is for the treatment of acute angioedema attacks in adults with hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency. Alongside, Ruconest was approved by the reimbursement committee, to be added on the Israel Health basket with no extra costs.
Under the agreement, MegaPharm will purchase its commercial supply of RUCONEST from Pharming at a supply price based on a percentage of net sales. The number of HAE patients in Israel is estimated at approximately 250. MegaPharm anticipate launching RUCONEST during Q1 of this year.
Sijmen de Vries, CEO of Pharming, commented: "MegaPharm is a strong commercialization partner for us and has a proven track record in this region with a strong presence in the immunology therapeutic area. We are looking forward to providing HAE patients in Israel with a new and innovative treatment.”
About RUCONEST and Hereditary Angiodema
RUCONEST (INN conestat alfa) is a recombinant version of the human protein C1 esterase inhibitor, and is produced with Pharming's proprietary transgenic technology. RUCONEST is approved in Europe for the treatment of acute angioedema attacks in patients with HAE, a genetic disorder in which the patient is deficient in or lacks a functional plasma protein C1 esterase inhibitor, resulting in unpredictable and debilitating episodes of intense swelling. The swelling may occur in one or more anatomical areas, including the extremities, face, trunk, genitals, abdomen and upper airway. The frequency and severity of HAE attacks vary and are most serious when they involve laryngeal edema, which can close the upper airway and cause death by asphyxiation. According to the U.S. Hereditary Angioedema Association, epidemiological estimates for HAE range from one in 10,000 to one in 50,000 individuals. RUCONEST is an investigational drug in the U.S. and has been granted orphan drug designation by the FDA both for the treatment of acute attacks of HAE and for prophylactic treatment of HAE.
About Pharming Group NV
Pharming Group NV is developing innovative products for the treatment of unmet medical needs. RUCONEST® (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of angioedema attacks in patients with HAE in all 27 EU countries plus Norway, Iceland and Liechtenstein, and is distributed in the EU by Swedish Orphan Biovitrum. RUCONEST® is partnered with Salix Inc. (NASDAQ: SLXP) in North America and a Biologics License Application (BLA) for RUCONEST® is under review by the U.S. Food and Drug Administration. The product is also being evaluated for various follow-on indications. Pharming has a unique GMP compliant, validated platform for the production of recombinant human proteins that has proven capable of producing industrial volumes of high quality recombinant human protein in a more economical way compared to current cell based technologies. In July 2013, the Platform was partnered with Shanghai Institute for Pharmaceutical Industry (SIPI), a Sinopharm Company, for joint global development of new products. Pre- clinical development and manufacturing will take place at SIPI and are funded by SIPI. Pharming and SIPI initially plan to utilise this platform for the development of rhFVIII for the treatment of Haemophilia A. Additional information is available on the Pharming website, www.pharming.com.
About MegaPharm
MegaPharm Ltd. is one of the leading private biotech, pharmaceutical and medical nutrition marketing companies in Israel with a strong biotech orientation, exclusively representing a number of major American and European pharmaceutical companies. MegaPharm has demonstrated dynamic sales growth by developing a strong company presence and expertise in select therapeutic areas, and diversified segments of the healthcare business. For more information see www.megapharm.co.il.
This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements.
lien ISRAEL FDA :
FDA Harmonization Project – Aligning Standards
One of the U.S.-Israel Science and Technology Foundation’s (USISTF) greatest successes in its mission to increase scientific development and strengthen economic relations is the U.S. Food and Drug Administration (FDA) Harmonization Project. The project brought about the alignment of American and Israeli standards in the areas as Good Clinical Practices (GCP), Good Manufacturing Practices (GMP), and Good Laboratory Practices (GLP).
In 1996, the USISTF provided $100,000 in funding to train over four hundred Israeli medical professional at the Ministry of Health. USISTF recognized the economic and social rewards of a simpler, more efficient clinical trials process. Israel has been a favored site for clinical studies, owing to its diverse population base, loyalty to a single HMO and relative ease of patient tracking. Historically, clinical studies in Israel have proven to be highly cost-effective, with high participant recruitment rates and much lower rate of patient drop out. Moreover, Israel ranks first in the world in several therapeutic areas and boasts a high quality medical environment.
Thus, increasing the number of clinical studies conducted by U.S. pharmaceutical companies in Israel would create a clear benefit to both nations.
In 1997, the Food and Drug Administration granted Israel recognition as a site for complete data acceptance for clinical studies with trials conducted for new drugs and medical devices in Israel. Israel's popularity as a site for clinical studies, particularly by U.S. multi-national companies, has grown exponentially since then. The USISTF’s investment in regulatory harmonization was a key element causing a boom of activity within the clinical trials industry; from a starting point of $15 million in net revenues in 1994, it had matured into a $300 million industry by 2005.
The Foundation's FDA Harmonization Project has compellingly demonstrated the mutual benefit, in terms of health and economic welfare, which the U.S. and Israel can derive from collaboration between their governments, industry, and research institutions. The opportunities and future potential of combined U.S. and Israeli endeavors in this particular industry are undoubtedly as great.
**Ruconest pris en charge en Hongrie:
http://www.ihs.com/products/global-insight/industry-economic-report?ID =1065985179
Le RUCONEST a un rapport cout-utilité supérieur a ses concurrents :
Source: http://scibite.com/site/library/2013_11/1/0/24278067.html
Kawalec P et al Postepy Alergol Dermatol. 2013 juin; 30 (3) :152-158. Epub 2013 le 20 juin
Conclusions de l'analyse : L'administration de Ruconest (R) dans l'angio-œdème attaques mortelles aiguës est économiquement justifiée du point de vue du payeur polonais de la santé, les résultats en baisse des coûts et est caractérisée par une probabilité plus élevée de coût-utilité comparaison avec Berinert (R)
* Le marché :
marché pour OAH aiguës est d'environ $ 230m en 2013 + 47 % par rapport à 2012,
marché US estimé à 370 millions de dollars + 13 % par rapport à 2012)
A noter que le RUCONEST est évalué sur un marché total de 1 739M€, la part de marché à 35% et les ventes optimales sont estimées à 687M€.
La marge est de 16% en Europe et 25% au US (Bénéfice après déduction des dépenses et dépenses de marketing) correspond à la part des bénéfices de l'entreprise sur les revenus futurs).
Si accord FDA, une commission supplémentaire de 30-40% sur le prix de vente des produits vendus sera accordée.
A noter que le marché connait une croissance a deux chiffres
* PHARM : Une bio opéable....
avec une forte prime à la clé (Viropharma est le concurent de PHARMING)
DUBLIN et Exton, Pennsylvanie 11 Novembre 2013 / PRNewswire / -
- Shire plc ( LSE : SHP , NASDAQ: expéd ) et ViroPharma Incorporated ( NASDAQ: VPHM ) annoncent aujourd'hui que leurs conseils d' administration ont approuvé à l'unanimité , et les sociétés ont conclu un accord de fusion aux termes duquel Shire d'acquérir toutes les actions en circulation de la société sur les maladies rares ViroPharma pour 50 $ par action en numéraire , pour un montant total d'environ 4,2 milliards de dollars. Le prix de l'action de 50 $ par la transaction représente une prime de 27 % au cours de clôture de l'action de ViroPharma , le vendredi 8 Novembre 2013, le dernier jour de bourse avant l'annonce , et une prime de 64% à cours de l'action de ViroPharma de $ 30,47 le 12 Septembre , 2013.
4
- http://www.reuters.com/article/2013/11/07/us-santarus-offer-idUSBRE9A61 BT20131107
Notez raison achat de Santarus par Salix
(Reuters) - Salix Pharmaceuticals Ltd (SLXP.O) will buy Santarus Inc (SNTS.O) for about $2.6 billion to boost its portfolio of drugs with a complementary set of products from the specialty pharmaceutical company.
* Des analyses confiants sur le dossier PHARMING GROUP (liste non exhaustive) :
- FIRST BERLIN vise 0.70 dans une note de 19/11/2013 (dernière étude)
www.pharming.com/index.php?act=dl&file=PHARM_NA-2013-11-19_EN.pdf
- KBC vise 0.22 et passe a acheter (pas arrivé depuis très
longtemps)
http://translate.googleusercontent.com/translate_c?depth=1&hl=fr &prev=/search%3Fq%3Diex%2B.nl%26newwindow%3D1%26client%3Dfirefox-a%26hs%3DpQ y%26rls%3Dorg.mozilla:fr:official%26channel%3Drcs&rurl=translate.google.fr&a mp;sl=nl&u=http://www.iex.nl/Aandeel-Koers/96535/Pharming-Group/adviezen.asp x&usg=ALkJrhgFwBZwYoP9mpNR0msVs9qMyI3OYA
* Consensus actualisés:
abc bourse : obj 0,18 cts, analystes -, avis -
La tribune : obj 0,46 cts, analystes 2, avis acheter
Fortunéo : obj 0,46 cts, analystes 2, avis acheter
Boursorama : obj 0,46 cts, analystes 1, avis acheter
le figaro : obj 0,46 cts, analystes 2, avis acheter
Reuters : obj 0,60 cts, analystes -, avis acheter
Markets : obj 0,70 cts, analystes 5, avis divers
First Berlin : obj 0,70 cts
Zone bourse: obj 0,82 cts, analystes 3, avis acheter
4 traders : obj 0,82 cts, analystes 3, avis acheter
Keytrade Bank : obj 0,82 cts, -
* des résultats en constante amélioration depuis 4 ans et un prévisionnel intéressant
Perspectives et projections faites de l'année 2013 à 2016 :
Chiffre d'affaires (M €) 8.15 / 19.69 / 13.48 / 58.28
Y-o-y N.A. de croissance - 25.00 % /141,5% / -31,5% / 332,3%
EBIT (en M €) -5,99 / 3,30 / -3,90 / 39,37
Marge EBIT -73,4% / 16,8% / -28,9% / 67,5%
Le résultat net (en M €) -14,85 / -3,99 / 2,97 / 34,89
EPS (dilué) (€) -0,04 / 0,01 / -0,01 / 0,10
FCF (m €) -13,78 / -7,25 / 2,93 / 18,73
Ratio d'endettement net 320,6% / 215,0% / 264,4% / 54,6%
Liquidités (en M €) 19,84 / 22,77 / 23,43 / 47,06
Message complété le 21/02/2014 17:19:12 par son auteur.
Répondre
|
Forum de discussion Pharming Group
201502271600 395963